Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: Results of a phase i dose-escalating study in patients with advanced solid malignancies

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1397-1403

  Schoffski P ^a   Dumez, H ^a   Ruijter, R ^b   Miguel Lillo, B ^c   Soto Matos, A ^c   Alfaro, V ^c   Giaccone, G ^b,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PHARMAMAR S A   (Spain)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ES 285; Hepatotoxicity; Marine compounds; Neurotoxicity; Pharmacokinetics; Phase I; Spisulosine

Indexed keywords

ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; ES 285; IL 0111; PM 95118; PREGABALIN; SPHINGOSINE DERIVATIVE; SPISULOSINE; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CHONDROSARCOMA; CLINICAL ARTICLE; COLORECTAL CANCER; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE NUMBNESS; FEET NUMBNESS; FEMALE; HAND PARESTHESIA; HUMAN; INJECTION SITE REACTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OVARY CANCER; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPIDS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 82455212061     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1612-1     Document Type: Article

References (15)

1. G Faircloth C Cuevas 2006 Kahalalide F and ES285: potent anticancer agents from marine molluscs Prog Mol Subcell Biol 43 363 379 17153351 10.1007/978-3-540-30880-5-16 1:CAS:528:DC%2BD28Xos1ymt7s%3D
2. Baird R, Clarke P, Workman P (2005) ES-285, a novel marine anticancer agent: Investigation of mechanism of action using gene expression microarrays. AACR Meet Abstr 2005:970
3. AM Sanchez S Malagarie-Cazenave N Olea D Vara C Cuevas I Diaz-Laviada 2008 Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation Eur J Pharmacol 584 237 245 18343365 10.1016/j.ejphar.2008.02.011 1:CAS:528:DC%2BD1cXksVarurg%3D
4. R Cuadros E Montejo de Garcini F Wandosell G Faircloth JM Fernandez-Sousa J Avilla 2000 The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers Cancer Lett 152 23 29 10754202 10.1016/S0304-3835(99)00428-0 1:CAS:528:DC%2BD3cXit1Whu7o%3D (Pubitemid 30169014)
5. M Salcedo C Cuevas JL Alonso G Otero G Faircloth JM Fernandez-Sousa J Avila F Wandosell 2007 The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway Apoptosis 12 395 409 17191124 10.1007/s10495-006-0573-z 1:CAS:528:DC%2BD2sXptFekuw%3D%3D (Pubitemid 46169919)
6. RD Baird J Kitzen PA Clarke A Planting S Reade A Reid L Welsh L Lopez Lazaro B de las Heras IR Judson SB Kaye F Eskens P Workman JS de Bono J Verweij 2009 Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors Mol Cancer Ther 8 1430 1437 19509256 10.1158/1535-7163.MCT-08-1167 1:CAS:528:DC%2BD1MXntVKgsLk%3D
7. Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J (2010) A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Invest New Drugs. doi: 10.1007/s10637-010-9529-9
8. Schöffski P, Grünwald V, Giaccone G et al (2008) Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors. Eur J Cancer, 6(12), ENA Meet Abstr 176
9. Massard C, Majem M, Soria J-C, Salazar R, Deutsch E, Garcia M, Oaknin A, Soto A, de las Heras B, Armand J-P (2007) Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors. AACR Meet Abstr 2007:A4
10. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
11. MW Den Brok B Nuijen DM Meijer E Millan C Manada JH Beijnen 2005 Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl PDA J Pharm Sci Technol 59 246 257 (Pubitemid 41346134)
12. MW Den Brok B Nuijen JL Garcia E Miranda P Calvo C Manada JH Beijnen 2006 Compatibility and stability of the novel anticancer agent ES-285 × HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices Pharmazie 61 21 24 (Pubitemid 43128770)
13. E Stokvis L Nan-Offeringa H Rosing L Lopez-Lazaro JL Acena E Miranda A Lyubimov BS Levine C D'Aleo JH Schellens JH Beijnen 2003 Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry J Mass Spectrom 38 548 554 12794877 10.1002/jms.469 1:CAS:528:DC%2BD3sXksVKqt7w%3D (Pubitemid 36665542)
14. AA Geldof SC Mastbergen RE Henrar GT Faircloth 1999 Cytotoxicity and neurocytotoxicity of new marine anticancer agents using in vitro assays Cancer Chemother Pharmacol 44 4 312 318 10447579 10.1007/s002800050983 1:CAS:528:DyaK1MXls1Kmsbk%3D (Pubitemid 29402201)
15. C Le Tourneau E Raymond S Faivre 2007 Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison Curr Pharm Des 13 33 3427 3439 18045196 10.2174/138161207782360573 1:CAS:528: DC%2BD2sXhsVOrs73O (Pubitemid 350201676)